ライフサイエンスコーパス: transplantation

1 ive therapies (local ablation, resection, or transplantation).

2 d risk of the combined end point of death or transplantation.

3 ays after allogeneic hematopoietic stem cell transplantation.

4 been noted in the context of ovarian tissue transplantation.

5 ad received consecutive allogeneic stem-cell transplantation.

6 ment might bridge to liver recovery or liver transplantation.

7 d its effect on the immune response to organ transplantation.

8 innervation was present by 7-10 months after transplantation.

9 estore liver function and bridge patients to transplantation.

10 an alternative to conventional donor corneal transplantation.

11 ith similar disease severity with or without transplantation.

12 were excluded from consideration for kidney transplantation.

13 HCC) and increasingly an indicator for liver transplantation.

14 ith significant mortality and morbidity post-transplantation.

15 ed risk factors for interim death or cardiac transplantation.

16 l trials of Treg therapy in liver and kidney transplantation.

17 rtic aneurysms, respectively underwent renal transplantation.

18 , little work has been done to optimize such transplantation.

19 lung preservation leading to successful lung transplantation.

20 tline the potential of precision medicine in transplantation.

21 32 and Ctip2, in vitro as well in vivo after transplantation.

22 e delisted compared with those who underwent transplantation.

23 lated cardiomyopathy, and 40% die or undergo transplantation.

24 e associated with HCC recurrence after liver transplantation.

25 could be useful in improving the outcome of transplantation.

26 tory data available before or at the time of transplantation.

27 erminant controlling T cell responses during transplantation.

28 e that can be lethal in the absence of liver transplantation.

29 ints to increase waitlist priority for liver transplantation.

30 ic conditions, or solid-organ or bone marrow transplantation.

31 rify the therapeutic value of CP blockade in transplantation.

32 N was shown to be present up to 4 days after transplantation.

33 hereditary NS group had NS recurrence after transplantation.

34 othelium injury during preservation and post-transplantation.

35 pre-transplant, expansion and infusion post-transplantation.

36 nical protocols for stem cell harvesting and transplantation.

37 most outspoken in the first year after lung transplantation.

38 genitors give rise to a myeloid disease upon transplantation.

39 oach leading to long-term success after lung transplantation.

40 The primary outcome was death or lung transplantation.

41 ng hypoxic-ischemic human diseases and organ transplantation.

42 urvival and hematopoietic recovery after HSC transplantation.

43 nors, (iii) wait time, and (iv) living donor transplantation.

44 fected cells before haematopoietic stem cell transplantation.

45 e died and 3 LQT3 patients underwent cardiac transplantation.

46 option for CMML remains allogeneic stem cell transplantation.

47 ly becoming the leading indication for liver transplantation.

48 that could not be transferred by bone marrow transplantation.

49 orneal epithelial dysfunction after surgical transplantation.

50 with FMF was 61 months (range, 16-81) after transplantation.

51 igher with chronic dialysis than after renal transplantation.

52 ntly and efficiently than he could do before transplantation.

53 r both age at transplantation and time since transplantation.

54 potential of stroma recovery to improve HSC transplantation.

55 cular assist device implantation, or cardiac transplantation.

56 holds for the management of BKV infection in transplantation.

57 mproving long-term outcomes after intestinal transplantation.

58 y aid in the assessment of a kidney prior to transplantation.

59 otential candidates for autologous stem cell transplantation.

60 tensive strategies with autologous stem cell transplantation.

61 able with allogeneic hematopoietic stem cell transplantation.

62 During the first year after renal transplantation, 14 patients developed severe infections

63 ts with HF were more likely to undergo heart transplantation (15/142 versus 1/147; P<0.001) or die du

64 ated patients more often received allogeneic transplantation (16.3% v 8.7%).

65 At transplantation, 401 patients were positive for IgA-aB2G

66 uccess of allogeneic hematopoietic stem cell transplantation, a key treatment for many disorders, is

67 variables routinely available prior to liver transplantation, a validated model of posttransplantatio

68 Blood group incompatible transplantation (ABOi) in children is rare as pretranspl

69 itor cells exhibited a long-term competitive transplantation advantage.

70 lementary systems of risk stratification for transplantation-age patients with PMF and integrate prog

71 Purpose To develop a prognostic system for transplantation-age patients with primary myelofibrosis

72 ted with an increased risk of death or heart transplantation (all Ps<0.001).

73 Allogeneic hematopoietic cell transplantation (allo-HCT) is indicated for patients wit

74 United Network for Organ Sharing multiorgan transplantation allocation policy allows sequestration o

75 imus levels predict worse outcomes postrenal transplantation, although the causal nature of this rela

76 rgy to rituximab, or severe infection) after transplantation among patients who underwent randomizati

77 from patients with PAH undergoing heart/lung transplantation and compared with tissue obtained from c

78 model combined with irradiation, bone marrow transplantation and in vivo imaging, we show that preser

79 The combination of bone marrow transplantation and local muscle radiation protection al

80 nt DCs occurs for at least 1 month following transplantation and may be the main source of alloantige

81 d formation of new red cell antibodies after transplantation and red cell incompatibility between don

82 The demand for organ transplantation and repair, coupled with a shortage of a

83 ortant for islet revascularization following transplantation and represents a novel clinical target f

84 ling approach that accounted for both age at transplantation and time since transplantation.

85 ese T cells proliferated modestly after skin transplantation and underwent relatively weak functional

86 en envisioned as a source of donor cells for transplantation and vectors for the delivery of gene the

87 ion is associated with a lower likelihood of transplantation and worse posttransplant outcomes.

88 tive immune responses in response to sepsis, transplantation, and autoimmunity, and preventing oxidat

89 l bleeding), hepatocellular carcinoma, liver transplantation, and liver-related death developed in 55

90 iver Disease score greater than 32, combined transplantation, and reoperation.

91 than twofold increased risk for death after transplantation, and with a threefold increased risk for

92 d represents a novel model to test UCB-based transplantation approaches for various diseases.

93 mal viability in evolution and in modern HSC transplantation approaches.

94 Following transplantation, appropriate vascular remodeling is cruc

95 tudies and referral for allogeneic stem cell transplantation are also discussed.

96 trends in cardiovascular events after kidney transplantation are poorly understood.

97 Patient and graft survival after pancreas transplantation are superior in higher volume centers.

98 SCB repair processes, supporting hBM34+ cell transplantation as a future therapeutic strategy for ALS

99 In mouse models of retroviral AML transplantation, as well as in retrospective analyses of

100 de versus placebo after autologous stem-cell transplantation (ASCT) was investigated for patients wit

101 core </=2) proceeded to autologous stem cell transplantation (ASCT) whereas PET-positive patients rec

102 tients could proceed to autologous stem cell transplantation (ASCT).

103 DEL or DHL who undergo autologous stem-cell transplantation (ASCT).

104 Competitive serial transplantation assays using Zfp521-deficient mice revea

105 t are associated with survival without liver transplantation at 90 and 180 days after initiation of c

106 eening at age 30 years within 2 years of the transplantation because of the additional risk for colon

107 bservable benefit at early time points after transplantation, both anatomic and functional improvemen

108 trauma (SLT), in ALF patients as a bridge to transplantation (BTT), and as definitive therapy for tox

109 tor free immunosuppressive therapy in kidney transplantation but is associated with a higher acute re

110 is associated with increased mortality after transplantation, but the effect of glycemic control on s

111 provide the first direct evidence that ENSC transplantation can modulate the enteric neuromuscular s

112 ficant therapeutic potential to prevent post-transplantation cancer in immunosuppressed patients.

113 .77; 95% CI, 0.62-0.97), and being seen at a transplantation center (HR, 0.77; 95% CI, 0.65-0.93).

114 es 18 to 24 years at the time of listing and transplantation compared to older and younger age groups

115 the number of patients awaiting solid organ transplantation continues to remain much higher than the

116 vere vision impairment As opposed to corneal transplantation; corneal collagen crosslinking (CXL) is

117 awal (ITN030ST) and Clinical Trials in Organ Transplantation (CTOT-03) studies.

118 outcomes were obtained up to 270 days after transplantation (DAT).

119 h is impacted by both donor supply and liver transplantation demand.

120 or less (HR 1.47, 1.11-1.95, p=0.0076), and transplantations done in 2000-05 compared with those don

121 In the clinical settings of islet and renal transplantation, donor exosomes with respective tissue s

122 After bone marrow transplantation, donor-derived immune cells can trigger

123 After kidney transplantation, early readmission is independently asso

124 CD4+ T cells early after hematopoietic cell transplantation effectively prevents GVHD while preservi

125 SLK transplantation exemplifies the trade-off between the pr

126 We corroborate this finding with transplantation experiments in European and North Americ

127 of the gut mycobiome was confirmed in fecal transplantation experiments: adult maternally separated

128 Bone marrow transplantation failed to rescue outgrowth.

129 tant cause of death and indication for liver transplantation (fatality).

130 um difficile infection with fecal microbiota transplantation (FMT) at a tertiary referral center betw

131 Fecal microbiota transplantation (FMT) from cancer patients who responded

132 Fecal microbiota transplantation (FMT) may improve dysbiosis; however, it

133 roducts in individuals after kidney or liver transplantation following current FDA bioequivalence met

134 Here we explore early trends in pediatric transplantation following KAS, including: (i) use of ped

135 ious complex vascular reconstructions before transplantation for midaortic syndrome and multiple aort

136 ing unrelated umbilical cord blood units for transplantation for non-malignant diseases relies on ant

137 received a single unit umbilical cord blood transplantation for non-malignant diseases reported to t

138 n necessary future studies to optimize organ transplantation for older people.

139 ng it a safe alternative to orthotopic liver transplantation for patients with a wide range of noncir

140 inally defined in the context of adult liver transplantation for patients with hepatocellular carcino

141 PRA is an indispensible measure of access to transplantation for sensitized candidates and is used as

142 Median time to transplantation for such patients is double that of unse

143 all patients who underwent LSG before kidney transplantation from 2011-2016 (n = 20).

144 Existing legislation allows organ transplantation from an HIV-infected donor under excepti

145 Renal transplantation (from the same BMT donor) was performed

146 progression, and the probability of corneal transplantation, graft failure, or both were calculated

147 ars did not differ significantly between the transplantation group and the RVD-alone group (81% and 8

148 Primary liver transplantation has been advocated as surgical treatment

149 The risk of SCC after organ transplantation has declined significantly since the mid

150 use of induction therapy in pediatric heart transplantation has increased.

151 Uterus transplantation has proven successful when performed wit

152 of DAMPs in directing the immune response to transplantation has suggested novel avenues for the trea

153 ion, graft and patient outcomes after kidney transplantation have improved considerably.

154 Rates of organ donation and transplantation have steadily increased in the United St

155 Hematopoietic cell transplantation (HCT) has been considered a curative the

156 Hematopoietic cell transplantation (HCT) has now been shown to be safe and

157 Hematopoietic cell transplantation (HCT) is curative for FA-related marrow

158 ytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known.

159 atched-related allogeneic hematopoietic cell transplantation (HCT) recently showed no difference betw

160 myeloablative allogeneic hematopoietic cell transplantation (HCT).

161 ening complications after hematopoietic cell transplantation (HCT).

162 Autologous hematopoietic stem cell transplantation (HSCT) and mesenchymal stromal cell ther

163 lls to use in early haematopoietic stem cell transplantation (HSCT) approaches for several genetic di

164 ized complication of hematopoietic stem cell transplantation (HSCT) associated with excessive complem

165 tion and autologous haematopoietic stem-cell transplantation (HSCT) compared with mobilisation follow

166 Allogeneic hematopoietic stem cell transplantation (HSCT) is a critically important therapy

167 utcome of allogeneic hematopoietic stem cell transplantation (HSCT) was monitored.

168 cation of allogeneic hematopoietic stem cell transplantation (HSCT), posing as a significant barrier

169 ure after allogeneic hematopoietic stem cell transplantation (HSCT).

170 cation of allogeneic hematopoietic stem cell transplantation (HSCT).

171 Young adult heart transplantation (HTx) recipients experience high mortali

172 al year of graft survival) within 3 years of transplantation in 19 450 deceased donor kidney transpla

173 rt that the efficiency of subcutaneous islet transplantation in a Lewis rat model is significantly im

174 c flow index following heterotrophic cardiac transplantation in a murine model of chronic rejection.

175 fter heterologous bilateral hand and forearm transplantation in an 8-year-old child with quadrimembra

176 sessed the effectiveness of murine UCB cells transplantation in busulfan-conditioned newborn MPS-I mi

177 ation of organs from HIV-infected donors for transplantation in Canada.

178 Parity in access to transplantation in children and improvements in strategi

179 We showed that islet transplantation in confined well-vascularized sites like

180 loss from recurrent hepatitis B after liver transplantation in patients with preexisting LAM resista

181 ed functional bioengineered livers for organ transplantation in preclinical studies.

182 In those who underwent transplantation in the 1983-1987 period, the unadjusted

183 6 (95% CI, 16.8-27.0) in those who underwent transplantation in the 2003-2007 period.

184 correlate with high dopaminergic yield after transplantation in vivo.

185 ceeded to allogeneic hematopoietic stem-cell transplantation, including 55% (six of 11) of transplant

186 Differential access to transplantation, increased posttransplant survival, and

187 helial cells for at least 4 to 6 weeks after transplantation into immunodeficient mouse hosts.

188 Following transplantation into mice, HCOs undergo morphogenesis an

189 Allograft transplantation into sensitized recipients with antidono

190 SCs after both TLR4 stimulation in vitro and transplantation into the infarcted heart.

191 Hematopoietic stem cell transplantation is a potential curative therapy for mali

192 Thymus transplantation is a promising strategy for the treatmen

193 Cardiac transplantation is an effective therapy for end-stage he

194 f donor-specific antibodies (DSA) after lung transplantation is associated with antibody mediated rej

195 mplemented in the past two decades, in which transplantation is indicated on the basis of large tumou

196 atory (Treg) cells as therapeutic targets in transplantation is largely focused on their harvesting p

197 chronic kidney disease, the option of organ transplantation is limited because of the scarce availab

198 e lymphatics, the function following cardiac transplantation is poorly understood.

199 osinophilic syndrome in patients after liver transplantation is rare, and a broad differential diagno

200 Renal transplantation is the preferred treatment for patients

201 maternal T cells in peripheral blood before transplantation, is detectable in a significant proporti

202 ter liver transplantation (LTx) or intestine transplantation (ITx) in small cohorts of children and c

203 ence of sex disparity in living donor kidney transplantation (LDKT) remains controversial.

204 rtant tool to facilitate living donor kidney transplantation (LDKT).

205 ield and endorsed by the American Society of Transplantation Liver and Intestine and Thoracic and Cri

206 he time to development of BOS or RAS in lung transplantation (low vs high LVD: 38.5 vs 86.0 months, P

207 For SPK transplantation, low (adjusted hazard ration [aHR], 1.55

208 be at higher risk of malignancy after liver transplantation (LT) compared to other LT recipients.

209 ma (HCC) recurrence and survival after liver transplantation (LT) in patients meeting Milan criteria

210 Liver transplantation (LT) is rarely indicated in the manageme

211 ncorporates alpha-fetoprotein (AFP) at liver transplantation (LT), microvascular invasion, and the su

212 e lung destruction ultimately requiring lung transplantation (LT).

213 improved spontaneously and 7 worsened (liver transplantation [LT] (n=5), deceased (n=2)).

214 predict acute cellular rejection after liver transplantation (LTx) or intestine transplantation (ITx)

215 Instead, referral for heart transplantation may offer their best chance at long-term

216 have important therapeutic ramifications for transplantation medicine.

217 ons and hydroxycarbamide, although stem cell transplantation might be a potentially curative therapy.

218 sked whether the results of neural stem cell transplantation might be improved by accommodating the p

219 04657 was shown in the immunodeficient mouse transplantation model.

220 In intraportal islet transplantation models using mouse and human islets, we

221 ransplantation, including 55% (six of 11) of transplantation-naive responders.

222 In transplantation, neuro-immune communication could signif

223 Moreover, post-transplantation non-cell-autonomous mechanisms restore t

224 r trough concentrations the first week after transplantation nor time to target trough concentration

225 Transplantations occurred between Jan 1, 2000, and Dec 3

226 Here, we have shown that transplantation of adipose-derived stem cells (ASCs) acc

227 lts Hematopoietic recovery was similar after transplantation of BM and PB (28-day neutrophil recovery

228 Although transplantation of cardiac MSCs and subcutaneous MSCs fr

229 To corroborate this idea, upon transplantation of FCSCs into a bone defect microenviron

230 Allogeneic transplantation of foreign organs or tissues has lifesav

231 Transplantation of genetically corrected HSCs into Ifnga

232 Furthermore, transplantation of hDF-EpiSC-loaded native de-cellulariz

233 Autologous transplantation of hematopoietic stem and progenitor cel

234 Transplantation of human hematopoietic stem and progenit

235 Transplantation of infected Cftr-deficient alveolar macr

236 At 3 weeks after transplantation of MSC sheets, results showed more bony

237 Here, we found that intrathecal transplantation of neural stem/precursor cells (NPCs) in

238 Transplantation of sheath tissues improves tendon repair

239 ing regimens (HR 1.36, 1.10-1.68, p=0.0041), transplantation of units with total nucleated cell dose

240 Furthermore, transplantation of WT bone marrow into miR-155KO mice mi

241 rbidity and mortality after orthotopic liver transplantation (OLT).

242 ted with allogeneic haematopoietic stem cell transplantation on a compassionate basis in four Europea

243 to suppress pathological T-cell responses in transplantation or autoimmunity.

244 s) from FA patients, either after autologous transplantation or infusion into immunodeficient mice.

245 limit T-cell survival (eg, autoimmunity and transplantation) or enhance T-cell survival (eg, vaccina

246 r cells during engraftment but also improves transplantation outcome without signs of adverse patholo

247 Differences in kidney transplantation outcomes across GN subtypes have rarely

248 of the intestinal environment may influence transplantation outcomes.

249 tion of vertebrate viral sequences following transplantation (P = 0.02).

250 Folic Acid for Vascular Outcome Reduction in Transplantation participants.

251 hemotherapy followed by autologous stem-cell transplantation, patients have relapses.

252 Data of all first kidney transplantation performed before 30 years of age between

253 Simultaneous liver-kidney (SLK) transplantation plays an important role in treating kidn

254 Current immunosuppression regimens in organ transplantation primarily inhibit T cells.

255 Data indicate that liver transplantation prolongs survival times of patient with

256 Heart transplantation recipients aged 2 to 40 years, transplan

257 nsplantation in 19 450 deceased donor kidney transplantation recipients with Medicare as primary paye

258 ty to apply precision medicine strategies in transplantation research.

259 1465384 and rs7248637), allogeneic stem cell transplantation, respiratory virus infection, and Asperg

260 .771), whereas survival outcomes after liver transplantation score obtains an AUC-ROC of 0.638 (95% C

261 ajor complication after allogeneic stem cell transplantation (SCT).

262 Hemodialysis, peritoneal dialysis, and transplantation services were funded publicly and free a

263 Thymus transplantation shows this requirement maps to IL-4Ralph

264 e that a 1 week delay between the lesion and transplantation significantly enhances graft vasculariza

265 The liver as transplantation site for human pancreatic islets is a ha

266 itable polymer to create an artificial islet transplantation site under the skin and supports islet s

267 In September 2015, the Transplantation Society convened a group of transplant c

268 ritical barrier hindering the application of transplantation strategies for a wide range of traumatic

269 Finally, bone marrow transplantation studies were performed to define the con

270 h specific cell ablation and embryonic heart transplantation studies, we identified a unique set of p

271 As of 18 months after transplantation surgery he is able to write and feed, to

272 ificantly longer in the group that underwent transplantation than in the group that received RVD alon

273 During allogeneic tissue transplantation, the inhibition of lymphangiogenesis has

274 In bilateral hand transplantations, this demands a 2 team approach and exp

275 he chance of the 10-year anniversary of face transplantation to reflect on the path traveled and to l

276 as led to a search for alternatives to liver transplantation to restore liver function and bridge pat

277 liable method with which to track ASCs after transplantation to skin wounds.

278 e best allocation criteria that would permit transplantation to the highest number of patients with s

279 by study site, type of organ, and time since transplantation) to receive 1 dose (control group) or 2

280 Folic Acid for Vascular Outcome Reduction in Transplantation trial, we determined whether plasma leve

281 e tubes expressing biliary markers following transplantation under the kidney capsule of immunocompro

282 During the reconstruction of our transplantation unit (April 2011-April 2014) we implemen

283 plete HLA-haploidentical donor hematopoietic transplantation using post-transplant cyclophosphamide w

284 lence in the population with data from liver transplantation waitlists to evaluate changes in the bur

285 Median follow-up after transplantation was 6.6 years (379 patient-years).

286 The median age at transplantation was 9 years, and the median follow-up wa

287 Allogeneic transplantation was allowed.

288 The interval risk of death or/cardiac transplantation was associated with poorer ventricular p

289 icant mutation in INF2 In this family, renal transplantation was associated with post-transplant TMA.

290 Survival from time of diagnosis or transplantation was estimated by using the Kaplan-Meier

291 Transplantation was performed in 257 patients.

292 hin the European Society of Blood and Marrow Transplantation, we conducted a prospective, multicenter

293 ng toward precision medicine in the field of transplantation will require transplant physicians to em

294 etransplantation vs 5 (9.4%) after the first transplantation with a median delay of 50 months and wer

295 Twelve patients with cDGS underwent transplantation with allogeneic cultured thymus.

296 the addition of sirolimus at 3 months after transplantation with concomitant reduction in tacrolimus

297 s human islet or stem cell-derived beta cell transplantation) without immunosuppression.

298 lent, with survival of 87% at 12 years after transplantation, without any mortality related to HBV re

299 of the leading causes of liver diseases and transplantation worldwide.

300 dministered every 2 months for 3 years after transplantation would prolong the duration of response.